Conte Matteo, Mao Boran, Tahir Sara, Rodriguez Armando, Hussain Sayed T
Medicine and Surgery, University of Padova, Padova, ITA.
Radiology and Biomedical Imaging, Yale New Haven Hospital, New Haven, USA.
Cureus. 2025 Jul 2;17(7):e87165. doi: 10.7759/cureus.87165. eCollection 2025 Jul.
We report the case of a 52-year-old woman with no prior psychiatric history who developed severe depressive symptoms shortly after starting evolocumab (Repatha) for lipid management. Her symptoms included persistent low mood and crying spells, which resolved completely after discontinuation of the medication. Her low-density lipoprotein (LDL)-cholesterol levels decreased significantly during this period. She was later switched to bempedoic acid and remained asymptomatic. This clinical course suggests a potential link between intensive LDL reduction and mood disturbances. While psychiatric side effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are rarely reported, this case raises awareness and underscores the need for mental health outcomes integration into future PCSK9 investigations.
我们报告了一例52岁女性患者，该患者既往无精神病史，在开始使用依洛尤单抗（Repatha）进行血脂管理后不久出现了严重的抑郁症状。她的症状包括持续情绪低落和哭泣发作，在停药后症状完全缓解。在此期间，她的低密度脂蛋白（LDL）胆固醇水平显著下降。她后来改用贝派地酸，此后一直无症状。这一临床过程提示了强化LDL降低与情绪障碍之间可能存在联系。虽然很少有关于前蛋白转化酶枯草溶菌素9型（PCSK9）抑制剂精神副作用的报道，但该病例提高了人们的认识，并强调了在未来PCSK9研究中纳入心理健康结果的必要性。
